MRC1 and neoplasm: The feature that p53 and MMR proteins modulate cellular responses upon DNA damage and the availability of genetically engineered human and murine cells present a potential means to develop strategies to circumvent the reduced responsiveness by re-sensitising or by hypersensitising p53-mutant tumours to therapeutic regimens.